New heart failure drug enters first human safety trial

NCT ID NCT07547540

Not yet recruiting Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This early-stage trial will test a single dose of a new drug called LY3971297 in 90 people with two types of heart failure: preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The main goal is to see if the drug is safe and what side effects occur. Participants will be monitored for about two months, including a 4-day hospital stay and 5 follow-up visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3971297
What this could lead to: If safe, this could pave the way for larger studies testing whether LY3971297 helps control heart failure symptoms.
What could go wrong: This is an early Phase 1 safety trial with only a single dose, so it is not designed to prove effectiveness. Side effects are unknown and the drug may not work in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE HEART FAILURE, DIASTOLIC HEART FAILURE, SYSTOLIC

Contacts and locations

Locations

ARENSIA Research Clinic at County Clinical Hospital, Cluj-Napoca

Cluj-Napoca, 400347, Romania
ARENSIA Research Clinic at Republican Clinical Hospital in Chisinau

Chisinau, 2025, Moldova
Henry Ford Health System

Detroit, Michigan, 48202, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
Institut de Cardiologie

Chisinau, 2005, Moldova
Kobe University Hospital

Kobe, 650-0017, Japan
Kyoto University Hospital

Kyoto, 606-8507, Japan
National Cerebral and Cardiovascular Center

Suita-shi, 564-8565, Japan
National Hospital Organization Kasumigaura Medical Center

Tsuchiura-shi, 300-8585, Japan
University Medical Center Groningen

Groningen, 9713 GZ, Netherlands
University of North Carolina, Division of Cardiology

Chapel Hill, North Carolina, 27599, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.